| Business Summary | | Ophidian
Pharmaceuticals,
Inc.
was
engaged
in
the
design,
development
and
commercialization
of
cost
effective
therapeutic
and
diagnostic
products
for
human
and
animal
use,
focusing
principally
on
products
for
the
prevention
and
treatment
of
infectious
diseases,
until
May
2000,
when,
due
to
lack
of
financing,
the
Company
took
action
to
cease
operations.
The
Company's
workforce
was
reduced
80%
by
laying
off
research,
development
and
operations
personnel.
Remaining
management
staff
was
retained
to
wind
down
clinical
trial
and
manufacturing
operations
and
to
continue
to
seek
potential
partners
having
strategic
interests
in
markets
served
by
the
Company's
products.
In
August
2001,
the
Company
completed
a
merger
with
Hemoxymed,
Inc.
The
merged
company
will
focus
on
Hemoxymed's
proprietary
therapeutic
process
for
increasing
tissue
oxygenation.
Diseases
involving
insufficient
oxygen
delivery,
including
chronic
heart
failure
and
emphysema,
affect
more
than
100
million
patients
worldwide. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | OPHD
was
engaged
in
the
research
and
development
of
therapeutic
and
diagnostic
products
for
human
and
animal
use,
with
an
emphasis
on
infectious
diseases.
In
May
2000,
the
Company
decided
to
cease
operations.
For
the
nine
months
ended
6/01,
revenues
totalled
$0,
down
from
$1.3
million.
Net
loss
decreased
77%
to
$432
thousand.
Revenues
reflect
the
absence
of
sales
from
patents.
Lower
loss
reflects
a
decrease
in
research
and
development
costs. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Peter Model, Ph.D., 67 | Chairman | Margaret Van Boldrik, Ph.D., 44 | VP
Corp. Devel., Director | Susan Maynard, 50 | Sec. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|